Solifenacin significantly improves all symptoms of overactive bladder syndrome.

Abstract

Overactive bladder syndrome (OAB) is a chronic condition characterised by urgency, with or without associated urge incontinence. Solifenacin succinate is a once daily, bladder selective antimuscarinic available in two doses (5 and 10 mg). The recommended dose is 5 mg once daily and can be increased to 10 mg once daily if 5 mg is well tolerated. This article presents pooled efficacy and safety data from four large, placebo-controlled, multinational phase III trials of solifenacin succinate with a total enrolment of over 2800 patients. Data from these trials show that solifenacin 5 and 10 mg once daily is significantly more effective than placebo at reducing urgency, incontinence, micturition frequency and nocturia and at increasing volume voided per micturition. Adverse events were mainly mild-to-moderate in all treatment groups. The results of these phase III trials support the use of solifenacin in the treatment of OAB.

• Authors: C R Chapple, L Cardozo, W D Steers, F E Govier
• Journal: International journal of clinical practice (Int J Clin Pract) Vol. 60 Issue 8 Pg. 959-66 (Aug 2006) ISSN: 1368-5031 [Print] India
• PMID: 16893438 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Muscarinic Antagonists
• Quinuclidines
• Tetrahydroisoquinolines
• Solifenacin Succinate

Topics

• Adolescent
• Adult
• Aged
• Analysis of Variance
• Clinical Trials, Phase III as Topic
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Multicenter Studies as Topic
• Muscarinic Antagonists (administration & dosage, adverse effects)
• Quality of Life
• Quinuclidines (administration & dosage, adverse effects)
• Randomized Controlled Trials as Topic
• Solifenacin Succinate
• Tetrahydroisoquinolines (administration & dosage, adverse effects)
• Treatment Outcome
• Urinary Bladder, Overactive (drug therapy)